Who we are
Depixus is a life-science tools company pioneering a cutting-edge magnetic force spectroscopy technology to unveil the intricate world of molecular interactions. Our MAGNA One instrument system can modulate and measure the forces involved in individual molecular interactions in real-time and on a massive scale. This groundbreaking capability allows researchers to explore the dynamics of biological mechanisms, opening new pathways to decode disease mechanisms and accelerate the development of more effective therapies.
Working at Depixus
We’re always on the lookout for talented people to help bring our mission to reality. We strive to be a great employer. Working with us, you’ll be part of a collaborative and close-knit team, where not only your experience matters, but also your energy, innovations, and creativity.
Meet our leadership team & board of directors
Leadership team
Gordon Hamilton co-founded Depixus and has led the company since its inception. He has played an important role in defining the company’s vision and strategy, has helped to raise over €50m to finance its activities to-date, and has contributed to the company’s core inventions both in instrumentation and biology. Prior to Depixus, he was Medical Director at ChemoCentryx, a Californian drug-discovery company (acquired by Amgen), where he helped the company to advance its novel chemokine-targeting drugs through Phases I and II of clinical development. Before ChemoCentryx, he worked as a medical doctor in emergency medicine in the UK. He has a first-class master’s degree in Physiological Sciences from the University of Oxford, degrees in Medicine and Surgery from Imperial College School of Medicine, and an MBA from INSEAD.
Steve Klose is a seasoned executive with 20+ years of experience commercializing cutting-edge technologies within the life sciences and biopharmaceutical industries. Before joining Depixus, he held key leadership roles at RedShiftBio, Bio-Techne, SciKon Innovation, Quanterix, and Meso Scale Discovery, driving rapid commercialization of innovative solutions. Steve is also adept at fundraising, having successfully secured venture capital. He holds a B.S. in Chemistry and an M.S. in Management from North Carolina State University.
Steve Allen has enjoyed a 30-year career with a track record of building a wide range of Life Science product and service companies, from start-ups to multinational corporations. Before his most recent role as CEO of DNAe, Steve held a number of leadership positions at PerkinElmer, Mettler-Toledo and LGC Forensics. Having led the acquisition of over 15 companies and the successful launch of more than fifty new scientific products and services, Steve has used his experience to assist early stage companies to make the step change from scientific innovation to commercial success. This includes the Next Generation Sequencing pioneer Solexa, where he was a Non-Executive Director and consultant, helping to scale the company to product launch and sale to Illumina. Steve has a PhD in Chemistry from the University of Nottingham.
Jimmy Ouellet joined Depixus early on as a molecular biologist to develop novel sample preparations as well as reagents to produce and analyze nucleic acid molecules on the technology developed by Depixus. His work has led to multiple patents related to either sample preparation or reagents that are currently part of the Depixus’ portfolio. Prior to joining Depixus, he completed his PhD at McGill University (Montréal) followed by a post-doctoral work at ETH (Zürich). Since joining Depixus, he was involved in building the biology team and he is now in charge innovation related to new applications of the Depixus MAGNA One instrument system.
Pascale Beurdeley is the Senior Vice President of Product Development at Depixus, bringing 27 years of experience in the biotechnology industry. She has spent 13 years in executive roles, leading R&D initiatives in oncology, neurology, and infectious disease programs, with expertise in molecular biology technologies such as NGS, qPCR, and Microarray. Prior to her current role, she served as Chief Scientific Officer at PathoQuest. Before that, she held the position of Executive Director of R&D, Genomics at DIAXONHIT (formerly Exonhit Therapeutics). Pascale holds a Ph.D. from the University of Strasbourg.
Thibault Vieille serves as VP of Engineering at Depixus. At Depixus, he has led the development of magnetic force spectroscopy instruments and consumables, from concept to product. Thibault joined Depixus in the company’s early days, starting as a Post-Doctoral Research Fellow at the Laboratory of Statistical Physics of the École Normale Supérieure, Paris, in the research group of the renowned biophysicists Vincent Croquette and David Bensimon. He holds a PhD in Quantum Physics from Ecole Polytechnique and master's degrees in Optical engineering and in Physics, both from Paris Saclay university.
Board of directors
Lachlan MacKinnon joined Oxford Sciences Innovation in 2015 as a member of the founding team. Whilst there, he made investments at the intersection of technology and biology including foundational seed investments in OMass Therapeutics, ONI, Spybiotech, Nucleome and Base Genomics which was acquired by Exact Sciences in 2020 for $410m. In 2020 he left to found his own company and joined the board of Depixus as part of the Series A.
Thibaut Roulon is a senior investment director at Bpifrance. He started his career as a scientist in a US biotech company developing cancer immunotherapeutics. In 2005 he joined Bioam Gestion, a venture capital firm investing in life science companies. In 2010, Bioam merged with Bpifrance Investissement, a leading French investment firm investing in SMEs and mid-Tier companies. Bpifrance manages several funds dedicated to life science investments, including InnoBio and InnoBio 2.
Thibaut is in charge of investments in life sciences companies at various stages (Seed, Venture, IPO, PIPE). He is a graduate of the Ecole Centrale de Paris and holds a PhD from the Pierre & Marie Curie University.
Ronald Lindsay is currently the Chief Executive Officer of Zebra Biologics, Inc., a company developing a disruptive new antibody generating platform. He previously served as Executive Vice President of Strategic Planning at Sequenom Inc, a company that pioneered the use of next generation sequencing for non-invasive prenatal diagnostics.
Prior to Sequenom, Ronald held a variety of senior biopharmaceutical positions, directing discovery and preclinical research efforts in cancer, neuroscience, and genomics. He has served as Vice President, Research and Development, and Chief Science Officer of diaDexus, Inc; has been a Senior Advisor at the German venture capital fund TVM Capital GmbH; was a Member of the Scientific Advisory Board of Merck Serono S.A, has held various senior management roles with Millennium Pharmaceuticals, Inc; and was a co-founder of Regeneron Pharmaceuticals, Inc., today a pharmaceutical company with a market capitalisation of ~$40bn. He began his industry career as Head of Cell Biology at the Sandoz Institute for Medical Research, University College in London. He has authored over 150 scientific articles and was recognized by the Institute for Scientific Information as one of the most highly cited neuroscientists of the 1990’s. He is also the holder of multiple patents. He has Ph.D. in Biochemistry from the University of Calgary and a B.Sc. (Honours) in Chemistry from the University of Glasgow.
Gordon Hamilton co-founded Depixus and has led the company since its inception. He has played an important role in defining the company’s vision and strategy, has helped to raise over €50m to finance its activities to-date, and has contributed to the company’s core inventions both in instrumentation and biology. Prior to Depixus, he was Medical Director at ChemoCentryx, a Californian drug-discovery company (acquired by Amgen), where he helped the company to advance its novel chemokine-targeting drugs through Phases I and II of clinical development. Before ChemoCentryx, he worked as a medical doctor in emergency medicine in the UK. He has a first-class master’s degree in Physiological Sciences from the University of Oxford, degrees in Medicine and Surgery from Imperial College School of Medicine, and an MBA from INSEAD.
Backed by...
Get in touch
Enquiry form
Send us a message via our online enquiry form
By email
Send us an email and we’ll get back to you as soon as possible
By phone
+33 (0)9 72 63 28 89
Here to help answer your questions
Or visit us
We’re headquartered in France, with our main offices & labs right in the heart of Paris. You’ll find us at: 3 impasse Reille, 75014 Paris